Home › Linfoma diffuso a grandi cellule B › Distretto di Columbia › Washington
Studi clinici su Linfoma diffuso a grandi cellule B a Washington, DC
12 studi su Linfoma diffuso a grandi cellule B cercano partecipanti presso sedi a Washington e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
In reclutamentoFase 2
- MedStar Georgetown University Hospital, Washington D.C.
- The Center for Cancer and Blood Disorders, Bethesda · a 7 mi di distanza
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
In reclutamentoFase 2
- Walter Reed National Military Medical Center, Bethesda · a 7 mi di distanza
- National Institutes of Health Clinical Center, Bethesda · a 7 mi di distanza
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- American Oncology Partners of Maryland Pa, Bethesda · a 7 mi di distanza
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
In reclutamentoFase 1/2
- National Institutes of Health Clinical Center, Bethesda · a 7 mi di distanza
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
In reclutamentoFase 3
- American Oncology Partners, P.A. ( Site 0185), Bethesda · a 7 mi di distanza
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
In reclutamentoFase 2
- Georgetown University Medical Center ( Site 0117), Washington D.C.
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
In reclutamentoFase 2
- National Institutes of Health Clinical Center, Bethesda · a 7 mi di distanza
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
In reclutamentoFase 1
- National Institutes of Health Clinical Center, Bethesda · a 7 mi di distanza
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
In reclutamentoFase 1/2
- Medstar Georgetown University Hospital, Washington D.C.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
In reclutamentoFase 3
- MedStar Georgetown University Hospital, Washington D.C.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- National Institute of Health, Bethesda · a 7 mi di distanza
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- National Institutes of Health Clinical Center, Bethesda · a 7 mi di distanza
Studi su Linfoma diffuso a grandi cellule B in altre città
- New York City, NY21 studi
- Baldwin Park, CA19 studi
- Chicago, IL18 studi
- Los Angeles, CA17 studi
- Houston, TX17 studi
- Boston, MA16 studi
- Milwaukee, WI16 studi
- Portland, OR15 studi
- Nashville, TN15 studi
- Philadelphia, PA15 studi
- Durham, NC14 studi
- Dallas, TX13 studi
Altri studi a Washington
- Cancro (tutti i tipi)58 studi
- Cancro del polmone non a piccole cellule55 studi
- Cancro al seno46 studi
- Cancro metastatico43 studi
- Cancro ai polmoni41 studi
- Cancro alla prostata38 studi
- Obesità33 studi
- Cancro colorettale29 studi
- Malattie cardiovascolari29 studi
- Cancro della vescica26 studi
- Leucemia mieloide acuta24 studi
- Linfoma23 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.